Drijkoningen, J. J. & Rohde, G. G. Pneumococcal infection in adults: burden of disease. Clin. Microbiol. Infect. 20, 45–51 (2014).
Weinberger, B., Herndler-Brandstetter, D., Schwanninger, A., Weiskopf, D. & Grubeck-Loebenstein, B. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis. 46, 1078–1084 (2008).
van Deursen, A. M. M. et al. Immunogenicity of the 13-valent pneumococcal conjugate vaccine in older adults with and without comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Clin. Infect. Dis. 65, 787–795 (2017).
van Werkhoven, C. H., Huijts, S. M., Bolkenbaas, M., Grobbee, D. E. & Bonten, M. J. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin. Infect. Dis. 61, 1835–1838 (2015).
Ridda, I. et al. Immunological responses to pneumococcal vaccine in frail older people. Vaccine 27, 1628–1636 (2009).
Kim, J. O. et al. Relationship between cell surface carbohydrates and intrastrain variation on opsonophagocytosis of Streptococcus pneumoniae. Infect. Immun. 67, 2327–2333 (1999).
Westerink, M. A., Schroeder, H. W. Jr. & Nahm, M. H. Immune responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination. Aging Dis. 3, 51–67 (2012).
Romero-Steiner, S. et al. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin. Vaccin. Immunol. 13, 165–169 (2006).
Pollard, A. J., Perrett, K. P. & Beverley, P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213–220 (2009).
Bonten, M. J. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 372, 1114–1125 (2015).
McLaughlin, J. M. et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin. Infect. Dis. 67, 1498–1506 (2018).
Heo, J. Y. et al. Effectiveness of pneumococcal vaccination against pneumococcal pneumonia hospitalization in older adults: a prospective, test-negative study. J. Infect. Dis. 225, 836–845 (2022).
Patterson, S. W. et al. A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults). Trials Vaccinol. 5, 92–96 (2016).
Suaya, J. A. et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine 36, 1477–1483 (2018).
Hsiao, A. et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against vaccine-type invasive pneumococcal disease in older adults. Vaccine 44, 126543 (2025).
Park, S. & Nahm, M. H. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. Infect. Immun. 79, 314–320 (2011).
Schenkein, J. G., Park, S. & Nahm, M. H. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 26, 5521–5526 (2008).
Adler, H., Ferreira, D. M., Gordon, S. B. & Rylance, J. Pneumococcal capsular polysaccharide immunity in the elderly. Clin. Vaccin. Immunol. 24, e00004–e00017 (2017).
Essink, B. et al. Pivotal Phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged >/=18 Years. Clin. Infect. Dis. 75, 390–398 (2022).
Janssen, L. M. A. et al. The clinical relevance of IgM and IgA anti-pneumococcal polysaccharide ELISA assays in patients with suspected antibody deficiency. Clin. Exp. Immunol. 205, 213–221 (2021).
van der Heiden, M. et al. Lower antibody functionality in middle-aged adults compared to adolescents after primary meningococcal vaccination: Role of IgM. Exp. Gerontol. 105, 101–108 (2018).
Simell, B. et al. Serum IgM antibodies contribute to high levels of opsonophagocytic activities in toddlers immunized with a single dose of the 9-valent pneumococcal conjugate vaccine. Clin. Vaccin. Immunol. 19, 1618–1623 (2012).
Southern, J. et al. Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England. PLoS One 13, e0195799 (2018).
Vissers, M. et al. Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in the Netherlands. PLoS One 13, e0194823 (2018).
van Sleen, Y. et al. Frailty is related to serum inflammageing markers: results from the VITAL study. Immun. Ageing 20, 68 (2023).
Simell, B. et al. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine 29, 1929–1934 (2011).
Raff, H. V. et al. Comparison of functional activities between IgG1 and IgM class-switched human monoclonal antibodies reactive with group B streptococci or Escherichia coli K1. J. Infect. Dis. 163, 346–354 (1991).
Shyur, S. D., Raff, H. V., Bohnsack, J. F., Kelsey, D. K. & Hill, H. R. Comparison of the opsonic and complement triggering activity of human monoclonal IgG1 and IgM antibody against group B streptococci. J. Immunol. 148, 1879–1884 (1992).
van der Heiden, M. et al. Novel intervention in the aging population: a primary meningococcal vaccine inducing protective IgM responses in middle-aged adults. Front. Immunol. 8, 817 (2017).
Frasca, D. & Blomberg, B. B. Aging affects human B cell responses. J. Clin. Immunol. 31, 430–435 (2011).
Shi, Y. et al. Regulation of aged humoral immune defense against pneumococcal bacteria by IgM memory B cell. J. Immunol. 175, 3262–3267 (2005).
Martin, V., Wu, Y. C., Kipling, D. & Dunn-Walters, D. K. Age-related aspects of human IgM(+) B cell heterogeneity. Ann. N. Y Acad. Sci. 1362, 153–163 (2015).
Cevirgel, A. et al. Identification of aging-associated immunotypes and immune stability as indicators of post-vaccination immune activation. Aging Cell 21, e13703 (2022).
Holodick, N. E., Vizconde, T., Hopkins, T. J. & Rothstein, T. L. Age-related decline in natural IgM function: diversification and selection of the B-1a cell pool with age. J. Immunol. 196, 4348–4357 (2016).
Boes, M., Prodeus, A. P., Schmidt, T., Carroll, M. C. & Chen, J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J. Exp. Med. 188, 2381–2386 (1998).
Gronwall, C., Vas, J. & Silverman, G. J. Protective roles of natural IgM antibodies. Front. Immunol. 3, 66 (2012).
Musher, D. M. et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. Clin. Infect. Dis. 17, 66–73 (1993).
Musher, D. M. et al. Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. Clin. Infect. Dis. 24, 441–446 (1997).
Goldblatt, D. et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study. J. Infect. Dis. 192, 387–393 (2005).
Balmer, P. et al. Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine. Clin. Vaccin. Immunol. 14, 1442–1450 (2007).
Ramos-Sevillano, E., Ercoli, G. & Brown, J. S. Mechanisms of naturally acquired immunity to Streptococcus pneumoniae. Front. Immunol. 10, 358 (2019).
Romero-Steiner, S. et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29, 281–288 (1999).
Hu, B. T. et al. Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae. Clin. Diagn. Lab. Immunol. 12, 287–295 (2005).
van der Maten, E., de Jonge, M. I., de Groot, R., van der Flier, M. & Langereis, J. D. A versatile assay to determine bacterial and host factors contributing to opsonophagocytotic killing in hirudin-anticoagulated whole blood. Sci. Rep. 7, 42137 (2017).
Lee, L. H., Frasch, C. E., Falk, L. A., Klein, D. L. & Deal, C. D. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 21, 2190–2196 (2003).
Aase, A. & Michaelsen, T. E. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand. J. Immunol. 39, 581–587 (1994).
Lottenbach, K. R. et al. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect. Immun. 67, 4935–4938 (1999).
Anttila, M., Voutilainen, M., Jantti, V., Eskola, J. & Kayhty, H. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118, 402–407 (1999).
Bardardottir, E., Jonsson, S., Jonsdottir, I., Sigfusson, A. & Valdimarsson, H. IgG subclass response and opsonization of Streptococcus pneumoniae after vaccination of healthy adults. J. Infect. Dis. 162, 482–488 (1990).
Gil, E., Noursadeghi, M. & Brown, J. S. Streptococcus pneumoniae interactions with the complement system. Front. Cell Infect. Microbiol. 12, 929483 (2022).
Cao, W. et al. Modelling biological age based on plasma peptides in Han Chinese adults. Aging 12, 10676–10686 (2020).
Gaya da Costa, M. et al. Age and sex-associated changes of complement activity and complement levels in a healthy Caucasian population. Front. Immunol. 9, 2664 (2018).
MacIntyre, C. R. et al. Frailty and immune response to pneumococcal vaccines among the elderly hospitalised patients. Int. J. Infect. Dis. 12 (2008).
Ravichandran, S. et al. Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults. Nat. Immunol. 25, 316–329 (2024).
Linley, E., Bell, A., Gritzfeld, J. F. & Borrow, R. Should Pneumococcal Serotype 3 be included in serotype-specific immunoassays?. Vaccines 7, 4 (2019).
van der Heiden, M. et al. Multiple vaccine comparison in the same adults reveals vaccine-specific and age-related humoral response patterns: an open phase IV trial. Nat. Commun. 15, 6603 (2024).
Hendriks, A. et al. Glycan-specific IgM is critical for human immunity to Staphylococcus aureus. Cell Rep. Med. 5, 101734 (2024).
Frenck, R. W. Jr. et al. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine 34, 3454–3462 (2016).
Van Baarle, D. et al. Preventing infectious diseases for healthy ageing: The VITAL public-private partnership project. Vaccine 38, 5896–5904 (2020).
Cooper, D. et al. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine 29, 7207–7211 (2011).
Elberse, K. E., Tcherniaeva, I., Berbers, G. A. & Schouls, L. M. Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin. Vaccin. Immunol. 17, 674–682 (2010).
Jones, S. et al. Assignment of Serotype-Specific IgG1, IgG2, and IgA weight-based antibody units to the human pneumococcal standard reference serum, 007sp. mSphere 4, e00400–e00419 (2019).
Quataert, S. A. et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2, 590–597 (1995).
Quataert, S. A. et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S(f). Clin. Diagn. Lab. Immunol. 11, 1064–1069 (2004).
Kloke, J. D. & McKean, J. W. Rfit: Rank-based estimation for linear models. R. J. 4, 57–64 (2012).
